Thrombotic microangiopathy-like disorder after living-donor liver transplantation: A single-center experience in Japan

World Journal of Gastroenterology

Volumn 17, Issue 14, 2011, Pages 1848-1857

  Hori, Tomohide ^a   Kaido, Toshimi ^a   Oike, Fumitaka ^a   Ogura, Yasuhiro ^a   Ogawa, Kohei ^a   Yonekawa, Yukihide ^a   Hata, Koichiro ^a   Kawaguchi, Yoshiya ^a   Ueda, Mikiko ^a   Mori, Akira ^a   Segawa, Hajime ^a   Yurugi, Kimiko ^a   Takada, Yasutsugu ^a   Egawa, Hiroto ^a   Yoshizawa, Atsushi ^a   Kato, Takuma ^b   Saito, Kanako ^b   Wang, Linan ^b   Torii, Mie ^b   Chen, Feng ^c   Baine, Ann Marie T ^c   Gardner, Lindsay B ^c   Uemoto, Shinji ^a   more..

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b MIE UNIVERSITY HOSPITAL   (Japan)

^c MAYO CLINIC   (United States)

Author keywords

A disintegrin like domain and metalloproteinase with thrombospondin type 1 motifs; Complication; Liver transplan tation; Thrombotic microangiopathy; Von Willebrand factor

Indexed keywords

BIOLOGICAL MARKER; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DIAGNOSTIC VALUE; FEMALE; HUMAN; INFANT; JAPAN; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PROTEIN EXPRESSION; RETRANSPLANTATION; THROMBOTIC MICROANGIOPATHY LIKE DISORDER; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

EID: 79955934810     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i14.1848     Document Type: Article

References (48)

1. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600
2. Tamura S, Sugawara Y, Matsui Y, Kishi Y, Akamatsu N, Kaneko J, Makuuchi M. Thrombotic microangiopathy in living-donor liver transplantation. Transplantation 2005; 80: 169-175
3. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause throm-botic thrombocytopenic purpura. Nature 2001; 413: 488-494
4. Fujikawa K, Suzuki H, McMullen B, Chung D. Purifcation of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662-1666
5. Gerritsen HE, Robles R, Lämmle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001; 98: 1654-1661
6. Savage B, Ginsberg MH, Ruggeri ZM. Infuence of fbrillar collagen structure on the mechanisms of platelet thrombus formation under fow. Blood 1999; 94: 2704-2715
7. Ruggeri ZM. Structure and function of von Willebrand factor. Thromb Haemost 1999; 82: 576-584
8. Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, Tamai H, Konno M, Kamide K, Kawano Y, Miyata T, Fujimura Y. Mutations and common polymorphisms in AD-AMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002; 99: 11902-11907
9. Soejima K, Mimura N, Hirashima M, Maeda H, Hamamoto T, Nakagaki T, Nozaki C. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem 2001; 130: 475-480
10. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a frst fuorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100
11. George JN. Tibor Greenwalt Award. The Oklahoma Throm-botic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: a program for patient care, education and research. Transfusion 2004; 44: 1384-1392
12. George JN. How I treat patients with thrombotic thrombo-cytopenic purpura-hemolytic uremic syndrome. Blood 2000; 96: 1223-1229
13. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic throm-bocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-397
14. Miyata R, Shimazu M, Tanabe M, Kawachi S, Hoshino K, Wakabayashi G, Kawai Y, Kitajima M. Clinical characteristics of thrombotic microangiopathy following ABO incompatible living donor liver transplantation. Liver Transpl 2007; 13: 1455-1462
15. Nishi H, Hanafusa N, Kondo Y, Nangaku M, Sugawara Y, Makuuchi M, Noiri E, Fujita T. Clinical outcome of throm-botic microangiopathy after living-donor liver transplantation treated with plasma exchange therapy. Clin J Am Soc Nephrol 2006; 1: 811-819
16. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994; 14: 495-504
17. Trimarchi HM, Truong LD, Brennan S, Gonzalez JM, Suki WN. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. Transplantation 1999; 67: 539-544
18. Humar A, Jessurun J, Sharp HL, Gruessner RW. Hemolytic uremic syndrome in small-bowel transplant recipients: the frst two case reports. Transpl Int 1999; 12: 387-390
19. Bonser RS, Adu D, Franklin I, McMaster P. Cyclosporin-induced haemolytic uraemic syndrome in liver allograft recipient. Lancet 1984; 2: 1337
20. Ulinski T, Charpentier A, Colombat M, Desconclois C, Mougenot B, Fremaux-Bacchi V, Suberbielle C, Deschênes G, Bensman A, Veyradier A. From humoral rejection to generalized thrombotic microangiopathy--role of acquired ADAMTS13 deficiency in a renal allograft recipient. Am J Transplant 2006; 6: 3030-3036
21. Llamas P, Romero R, Cabrera R, Sanjuán I, Forés R, Fernán-dez MN. Management of thrombotic microangiopathy following allogeneic transplantation: what is the role of plasma exchange? Bone Marrow Transplant 1997; 20: 305-306
22. Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, Girma JP, Azoulay E, Brun-Buisson C, Fakhouri F, Mira JP, Oksenhendler E, Poullin P, Rondeau E, Schleinitz N, Schlemmer B, Teboul JL, Vanhille P, Vernant JP, Meyer D, Veyradier A. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109: 2815-2822
23. Egawa H, Teramukai S, Haga H, Tanabe M, Fukushima M, Shimazu M. Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology 2008; 47: 143-152
24. Egawa H, Ohmori K, Haga H, Tsuji H, Yurugi K, Miyaga-wa-Hayashino A, Oike F, Fukuda A, Yoshizawa J, Takada Y, Tanaka K, Maekawa T, Ozawa K, Uemoto S. B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation. Liver Transpl 2007; 13: 579-588
25. Hori T, Uemoto S, Takada Y, Oike F, Ogura Y, Ogawa K, Miyagawa-Hayashino A, Yurugi K, Nguyen JH, Hori Y, Chen F, Egawa H. Does a positive lymphocyte cross-match contraindicate living-donor liver transplantation? Surgery 2010; 147: 840-844
26. Austin GL, Sasaki AW, Zaman A, Rabkin JM, Olyaei A, Ruimy R, Orloff SL, Ham J, Rosen HR. Comparative analysis of outcome following liver transplantation in US veterans. Am J Transplant 2004; 4: 788-795
27. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8: 765-774
28. Park JB, Kwon CH, Choi GS, Chun JM, Jung GO, Kim SJ, Joh JW, Lee SK. Prolonged cold ischemic time is a risk factor for biliary strictures in duct-to-duct biliary reconstruction in living donor liver transplantation. Transplantation 2008; 86: 1536-1542
29. Rana A, Hardy MA, Halazun KJ, Woodland DC, Ratner LE, Samstein B, Guarrera JV, Brown RS Jr, Emond JC. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant 2008; 8: 2537-2546
30. Mor E, Jennings L, Gonwa TA, Holman MJ, Gibbs J, Solomon H, Goldstein RM, Husberg BS, Watemberg IA, Klintmalm GB. The impact of operative bleeding on outcome in transplantation of the liver. Surg Gynecol Obstet 1993; 176: 219-227
31. Ben-Haim M, Emre S, Fishbein TM, Sheiner PA, Bodian CA, Kim-Schluger L, Schwartz ME, Miller CM. Critical graft size in adult-to-adult living donor liver transplantation: impact of the recipient's disease. Liver Transpl 2001; 7: 948-953
32. Yao FY, Saab S, Bass NM, Hirose R, Ly D, Terrault N, Lazar AA, Bacchetti P, Ascher NL, Roberts JP. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology 2004; 39: 230-238
33. Rhee C, Narsinh K, Venick RS, Molina RA, Nga V, Engelhardt R, Martín MG. Predictors of clinical outcome in children undergoing orthotopic liver transplantation for acute and chronic liver disease. Liver Transpl 2006; 12: 1347-1356
34. Iida T, Yagi S, Taniguchi K, Hori T, Uemoto S, Yamakado K, Shiraishi T. Signifcance of CT attenuation value in liver grafts following right lobe living-donor liver transplantation. Am J Transplant 2005; 5: 1076-1084
35. Rerolle JP, Akposso K, Lerolle N, Mougenot B, Ponnelle T, Rondeau E, Sraer JD. Tacrolimus-induced hemolytic uremic syndrome and end-stage renal failure after liver transplantation. Clin Transplant 2000; 14: 262-265
36. Singh N, Gayowski T, Marino IR. Hemolytic uremic syndrome in solid-organ transplant recipients. Transpl Int 1996; 9: 68-75
37. Ramasubbu K, Mullick T, Koo A, Hussein M, Henderson JM, Mullen KD, Avery RK. Thrombotic microangiopathy and cytomegalovirus in liver transplant recipients: a case-based review. Transpl Infect Dis 2003; 5: 98-103
38. Akamatsu N, Sugawara Y, Tamura S, Togashi J, Kaneko J, Makuuchi M. Late mortality from thrombotic microangiopathy after liver transplantation: report of a case. Surg Today 2007; 37: 345-348
39. Oya H, Sato Y, Yamamoto S, Nakatsuka H, Kobayashi T, Watanabe T, Kokai H, Hatakeyama K. Thrombotic microan-giopathy after ABO-incompatible living donor liver trans-plantation: a case report. Transplant Proc 2008; 40: 2549-2551
40. Takada Y, Haga H, Ito T, Nabeshima M, Ogawa K, Kasahara M, Oike F, Ueda M, Egawa H, Tanaka K. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients. Transplantation 2006; 81: 350-354
41. Saito T, Egawa H, Kudo T, Takakura S, Fujihara N, Iinuma Y, Ichiyama S. Pre-transplant risk factors predicting post-transplant cytomegalovirus infection in liver transplant recipients. Transpl Int 2007; 20: 419-424
42. Baid S, Pascual M, Williams WW Jr, Tolkoff-Rubin N, Johnson SM, Collins B, Chung RT, Delmonico FL, Cosimi AB, Colvin RB. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999; 10: 146-153
43. Matsukura T, Yokoi A, Egawa H, Kudo T, Kawashima M, Hi-rata Y, Tanaka H, Kagajo K, Wada H, Tanaka K. Signifcance of serial real-time PCR monitoring of EBV genome load in living donor liver transplantation. Clin Transplant 2002; 16: 107-112
44. Ueda M, Uemoto S, Inomata Y, Okajima H, Hashida T, Tanaka K, Yamaoka Y. A proposal of FK506 optimal dosing in living related liver transplantations. Transplantation 1995; 60: 258-264
45. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991; 325: 398-403
46. Hori T, Egawa H, Takada Y, Oike F, Ogura Y, Ogawa K, Kaido T, Toshimitsu Y, Yagi S, Iida T, Nguyen JH, Uemoto S. Fatal impact of lymphocyte cross-matching upon humoral rejection after adult living related liver transplantation. Transpl Int 2010; 23: 338-340
47. Nakazawa Y, Hashikura Y, Urata K, Ikegami T, Terada M, Yagi H, Ishizashi H, Matsumoto M, Fujimura Y, Miyagawa S. Von Willebrand factor--cleaving protease activity in throm-botic microangiopathy after living donor liver transplantation: a case report. Liver Transpl 2003; 9: 1328-1333
48. Banno S, Ito Y, Tanaka C, Hori T, Fujimoto K, Suzuki T, Hashimoto T, Ueda R, Mizokami M. Quantifcation of red blood cell fragmentation by the automated hematology analyzer XE-2100 in patients with living donor liver transplantation. Clin Lab Haematol 2005; 27: 292-296